What Researchers Did
Researchers investigated the role of S100A9 protein in osteonecrosis of the femoral head (ONFH) and how hyperbaric oxygen therapy (HBOT) affects its levels.
What They Found
The study found that serum S100A9 levels decreased in ONFH patients after hyperbaric oxygen therapy. Patients with ONFH showed increased S100A9, vascular endothelial growth factor (VEGF), and other markers, while osteocalcin levels were reduced compared to healthy individuals. Higher S100A9 levels were linked to more advanced ONFH stages and a history of glucocorticoid use or alcohol consumption, and in lab tests, S100A9 hindered blood vessel formation.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This study's findings are based on a molecular mechanism investigation and require confirmation through larger clinical trials to establish their direct applicability to patient care.